Pfizer expects to generate revenue of $15 billion, or a quarter of its total revenue, this year from sales of its coronavirus vaccine, co-developed by its German partner BioNTech.
She added that its sales of the vaccine, which is on its way to become the company’s best-selling product this year, may exceed $15 billion if the company signs new contracts to supply doses, knowing that the company seeks to produce about 2 billion doses of the vaccine in 2021.
Pfizer is now launching a study to determine whether applying a third dose of its coronavirus vaccine about 6 to 12 months after the initial doses is applied will extend and improve the effectiveness of the vaccine against the most infectious strains of the virus that have spread around the world, as the vaccine is currently applied in two doses separated by a period of 3 weeks, and Pfizer expects to provide about 200 million doses to the US government by the end of next May.
It is worth noting that its vaccine works with synthetic mRNA technology, which activates immunity against the virus, and is the first vaccine to be approved for emergency use in the United States, which marks the first approval by the regulatory authorities for this new treatment technology.
It is expected that a flu vaccine that works with this technology will be on the market by 2025, and Pfizer expects its sales in 2021 to range between 59.4 to 61.4 billion dollars, the company also raised its full-year adjusted earnings predictions by 10 cents, to about 3.10 to $3.20 per share.